This approach can help overcome the short half-life of the TRAIL.3–5 By utilising gene therapy to deliver the TRAIL gene, cancer cells can continuously produce the TRAIL protein, overcoming the short half-life of the TRAIL and achieving a more optimal concentration of the TRAIL at the tumour site. This evidence concerns the gene TNFSF10 and cancer.